News Article
Minnesota Physician Article: Vanquish Water Vapor Ablation System
November 13, 2023
We’re pleased to announce the October 2023 issue of Minnesota Physician features an article by our CMO, Dr. Christopher Dixon, on our Vanquish Water Vapor Ablation System for the treatment of prostate cancer.
Discover this breakthrough technology’s accelerated path to commercialization, what the patient can expect to experience, the three Minnesota sites (and their investigators) participating in our ongoing VAPOR 2 pivotal trial, and more.
About Francis Medical
Francis Medical is committed to developing urological cancer treatments that are tough on cancer and gentle on patients, with a compassionate belief that minimally invasive therapies can effectively treat cancerous tissue. The company’s foundation is a tribute to and legacy of the inventor’s father, Francis Hoey, who endured prostate cancer treatments that had harsh implications on his everyday living before the disease took his life in 1991. Unfortunately, current prostate cancer treatments are not much different from what Francis Hoey encountered, with the typical side effects including urinary incontinence and erectile dysfunction. In contrast, water vapor technology applies the thermal energy stored in sterile water vapor to cancerous tissue via a simple transurethral procedure, potentially minimizing life-altering side effects. For more information on Francis Medical, visit www.francismedical.com or call (763) 951-0370.
Recent Posts
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System
Press Release: Francis Medical Announces Completion of Enrollment in the VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
Press Release: Francis Medical Announces Close of Record $80 Million Series C Equity Financing
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.